ariana
07-17-2018, 01:01 AM
Clinical trial results of tucatinib with T-DM1 shows promise in treating HER2+ breast cancer.
Phase 1b clinical trial results published in*JAMA Oncology*show promise for the combination of tucatinib (formerly ONT-380) with T-DM1 against heavily pretreated HER2-positive breast cancer. Of 57 patients treated, 48 percent responded to the combination, with cancer control of median 8.2 months. Importantly, tucatinib acted against brain metastases stemming from HER2+ breast cancer, a major cause of mortality from the disease.
CLICK TO READ MORE:
https://www.news-medical.net/news/20180711/Clinical-trial-results-of-tucatinib-with-T-DM1-shows-promise-in-treating-HER22b-breast-cancer.aspx
Phase 1b clinical trial results published in*JAMA Oncology*show promise for the combination of tucatinib (formerly ONT-380) with T-DM1 against heavily pretreated HER2-positive breast cancer. Of 57 patients treated, 48 percent responded to the combination, with cancer control of median 8.2 months. Importantly, tucatinib acted against brain metastases stemming from HER2+ breast cancer, a major cause of mortality from the disease.
CLICK TO READ MORE:
https://www.news-medical.net/news/20180711/Clinical-trial-results-of-tucatinib-with-T-DM1-shows-promise-in-treating-HER22b-breast-cancer.aspx